All In Biotech

Drug Trial Radar · NCT05217628

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

A Phase II/III, Multicentre, 8-week run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, With a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 mg Basimglurant in Patients With Pain Associated With Trigeminal Neuralgia With Suboptimal Response to Their Current Anti-pain Therapy.

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

166

Actual

Start

Jan 11, 2022

Primary completion

Feb 2, 2027

Study completion Apr 24, 2027

Sponsor

Lead sponsor
Noema Pharma AGIndustry
Sponsor type
Industry
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.

Conditions

  • Trigeminal Neuralgia

Interventions

  • BasimglurantDrug

    Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability. Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo. OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1.

  • PlaceboOther

    Participant randomized to receive matching placebo once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Period 1: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.Time frame: 8 weeks
  2. Period 2: Time to Loss of Efficacy or pain recurrence defined as the confirmed increase in the number of weekly paroxysms or re-emergence of continuous pain and/or the need for rescue medication.Time frame: 12 weeks
  3. Open Label Extension: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.Time frame: 52 weeks

Locations

34 sites in 8 countries. Site status is shown where the registry gives one.

  • Kaizen Brain Center (Site #: 1001)

    La Jolla, California

  • L & A Morales Healthcare INC (Site#: 1011)

    Miami, Florida

  • University of South Florida (Site #: 1002)

    Tampa, Florida

  • Vista Clinical Research,LLC (Site#: 1010)

    Newnan, Georgia

  • Beth Israel Deaconess Medical Center (Site #: 1004)

    Boston, Massachusetts

  • Altea Research - Nevada - ClinEdge - PPDS (Site #1006)

    Las Vegas, Nevada

  • Columbia University - Irving Medical Center (Site #: 1008)

    New York, New York

  • University of Cincinnati (Site #: 1007)

    Cincinnati, Ohio

  • Danish Headache Center (Site #: 1201)

    Glostrup Municipality, Denmark

  • Universitätsklinikum Bonn (Site #: 1707)

    Bonn, Germany

  • Azienda Ospedaliera Universitaria Careggi (Site #: 1806)

    Florence, Italy

  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta (Site #: 1804)

    Milan, Italy

  • Università Campus Bio Medico Di Roma (Site #: 1805)

    Rome, Lazio, Italy

  • IRCCS San Raffaele Pisana (Site #: 1801)

    Rome, Lazio, Italy

  • La Sapienza-Università di Roma-Policlinico Umberto I (Site #: 1802)

    Rome, Lazio, Italy

  • Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ) Zespo (Site #: 2602)

    Dąbrowa Górnicza, Poland

  • Centrum Medyczne Linden (Site #: 2605)

    Krakow, Poland

  • FutureMeds - Lodzi - PPDS (Site #: 2606)

    Lodz, Poland

  • Prywatny Gabinet Lekarski U. Chyrchel-Paszkiewicz (Site #: 2604)

    Lublin, Poland

  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak (Site #: 2601)

    Wroclaw, Poland

  • Hospital Universitario Fundacion Jimenez Diaz (Site #: 1903)

    Madrid, Madrid, Spain

  • Hospital Universitario La Paz - PPDS (Site #: 1907)

    Madrid, Madrid, Spain

  • Hospital Universitario Virgen del Rocio - PPDS (Site #: 1904)

    Seville, Sevilla, Spain

  • Hospital Clinico Universitario de Valencia (Site #: 1906)

    Valencia, Valencia, Spain

  • Afyon Kocatepe University Faculty of Medicine (Site #: 9005)

    Afyonkarahisar, Turkey (Türkiye)

  • Uludag University Faculty of Medicine Hospital (Site #: 9001)

    Bursa, Turkey (Türkiye)

  • Istanbul University Istanbul Medical Faculty Hospital (Site #: 9003)

    Istanbul, Turkey (Türkiye)

  • Bagcilar Medipol Mega University Hospital (Site #: 9002)

    Istanbul, Turkey (Türkiye)

  • Kocaeli University Faculty of Medicine Hospital (Site #: 9004)

    Kocaeli, Turkey (Türkiye)

  • Mersin University Faculty of Medicine Hospital (Site #: 9007)

    Mersin, Turkey (Türkiye)

  • Duzce University Health Application and Research Center (9008)

    Düzce, Düzce, Turkey (Türkiye)

  • Selcuk University Medical Faculty (Site #: 9006)

    Selçuklu, Konya, Turkey (Türkiye)

  • St. Thomas' Hospital (Site #: 2504)

    London, London, United Kingdom

  • St Pancras Clinical Research (Site #: 2503)

    London, Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.